Bristol Myers (BMY.US) shares are up 4% ahead of the week’s final session on Wall Street after the drugmaker won approval from the U.S. Food and Drug Administration for its novel drug Cobenfa as a treatment for schizophrenia in adults. Analysts have commented that the FDA approval could help Bristol approve its acquisition of Karuna Therapeutics, which would theoretically expand BMY’s sales capabilities.
The FDA-approved drug is notable for being the first antipsychotic drug to target cholinergic receptors rather than dopamine receptors, which could be safer for patients in some situations. It is the first approved drug for schizophrenia in 30 years.
The stock is gaining ahead of the open and is trading well above the 200-day EMA (golden line on the chart), which could define the overall trend in the stock over the long term. Source: xStatio
Applied Digital accelerates growth. Shares rise by nearly 20%.
DAX: DE40 tries to hold the momentum 📈Brenntag and ArcelorMittal under pressure
Delta Airlines stock lifts off after earnings✈️
Stock of the Week - Super Micro Computer (09.10.2025)
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.
